Providence researchers contribute study findings at ASCO 2024 meeting, May 31- June 3

Researchers at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, contributed abstracts and participated in presentations at the 2024 ASCO Annual Meeting in Chicago, May 31-June 3.

The ASCO (American Society of Clinical Oncology) Annual Meeting is pivotal for advancing cancer research because it serves as a premier platform for oncologists, researchers and health care professionals to share groundbreaking research, treatments and emerging clinical practices. This convergence of experts fosters collaboration and helps accelerate the translation of research findings into clinical applications. 

Read on to find out who contributed to abstracts this year and to learn about some of the latest studies. 

Clinical Science Symposium (Oral Presentation) 

Head and Neck Cancer 

Abstract 6009: Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group | Bryan Bell, M.D., D.D.S., FACS, et al.  

Poster Sessions 

Lung Cancer

Abstract 8090: Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC) | Rachel Sanborn, M.D., et al. 

Abstract TPS8118: A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC | Rachel Sanborn, M.D., et al. 

Abstract TOS8650: AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors | Rom Leidner, M.D., et al. 

Abstract 8556: A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors | Matthew Taylor, M.D., et al.  

Gastrointestinal Cancer—Colorectal and Anal 

Abstract 3556: Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites | Rachel Sanborn, M.D., et al. 

Symptom Science and Palliative Care 

Abstract 12141: Pilot evaluation of portable scalp cooling for chemotherapy-associated alopecia in early-stage breast cancer | David Page, M.D., Alison Conlin, M.D., et al. 

Developmental Therapeutics—Immunotherapy 

Abstract TPS2689: A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors | Brendan Curti, M.D., et al.  

Abstract 2615: A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors | Brendan Curti, M.D., et al. 

Abstract: 2623: A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab | Brendan Curti, M.D., et al. 

Abstract 2542: Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors | Rom Leidner, M.D., et al. 

Abstract TPS2677: An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT‑112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation | Rom Leidner, M.D., et al.  

Abstract 2602: Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors | Matthew Taylor, M.D., et al.